In HER2-mutant patients with NSCLC undergoing first-line pemetrexed-based chemotherapy, the ORR was 36% and median PFS was 5.1 months, resembling the KRAS-mutant/EGFR-mutant group in terms of PFS but differing significantly from the ALK/ROS1 rearrangement group (p = 0.004) [29]. Here, KRAS is linked to non-small cell lung carcinoma.